BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: O'Leary JG, Kaneku H, Jennings LW, Bañuelos N, Susskind BM, Terasaki PI, Klintmalm GB. Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl 2013;19:973-80. [PMID: 23780820 DOI: 10.1002/lt.23687] [Cited by in Crossref: 92] [Cited by in F6Publishing: 79] [Article Influence: 10.2] [Reference Citation Analysis]
Number Citing Articles
1 Xu Q, Shrum B, Leckie S, Skaro A, McAlister VC. The impact of alloantibodies directed against the second donor on long-term outcomes of repeat liver transplantation. Hepatobiliary Surg Nutr 2019;8:246-52. [PMID: 31245404 DOI: 10.21037/hbsn.2019.01.14] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
2 Engels EA, Jennings LW, Everly MJ, Landgren O, Murata K, Yanik EL, Pfeiffer RM, Onaca N, Klintmalm GB. Donor-specific Antibodies, Immunoglobulin-free Light Chains, and BAFF Levels in Relation to Risk of Late-onset PTLD in Liver Recipients. Transplant Direct 2018;4:e353. [PMID: 30123826 DOI: 10.1097/TXD.0000000000000792] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
3 Lee BT, Fiel MI, Schiano TD. Antibody-mediated rejection of the liver allograft: An update and a clinico-pathological perspective. J Hepatol 2021:S0168-8278(21)01957-7. [PMID: 34343613 DOI: 10.1016/j.jhep.2021.07.027] [Reference Citation Analysis]
4 O'Leary JG. Donor-specific alloantibodies in liver transplantation: how should we define and improve long-term success? Transpl Int 2015;28:1359-61. [PMID: 26284821 DOI: 10.1111/tri.12661] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
5 Vionnet J, Sempoux C, Pascual M, Sánchez-fueyo A, Colmenero J. Donor-specific antibodies in liver transplantation. Gastroenterología y Hepatología 2020;43:34-45. [DOI: 10.1016/j.gastrohep.2019.09.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
6 Kim PT, Demetris AJ, O'Leary JG. Prevention and treatment of liver allograft antibody-mediated rejection and the role of the 'two-hit hypothesis'. Curr Opin Organ Transplant 2016;21:209-18. [PMID: 26918881 DOI: 10.1097/MOT.0000000000000275] [Cited by in Crossref: 39] [Cited by in F6Publishing: 3] [Article Influence: 6.5] [Reference Citation Analysis]
7 Iacob S, Cicinnati VR, Lindemann M, Heinemann FM, Radtke A, Kaiser GM, Kabar I, Schmidt HH, Baba HA, Beckebaum S. Donor-Specific Anti-HLA Antibodies and Endothelial C4d Deposition-Association With Chronic Liver Allograft Failure. Transplantation 2015;99:1869-75. [PMID: 25706274 DOI: 10.1097/TP.0000000000000613] [Cited by in Crossref: 30] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
8 Matsumoto CS, Rosen-Bronson S. Donor-specific antibody and sensitized patients in intestinal transplantation. Curr Opin Organ Transplant 2021;26:245-9. [PMID: 33528224 DOI: 10.1097/MOT.0000000000000853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 O'Leary JG, Demetris AJ, Friedman LS, Gebel HM, Halloran PF, Kirk AD, Knechtle SJ, McDiarmid SV, Shaked A, Terasaki PI, Tinckam KJ, Tomlanovich SJ, Wood KJ, Woodle ES, Zachary AA, Klintmalm GB. The role of donor-specific HLA alloantibodies in liver transplantation. Am J Transplant 2014;14:779-87. [PMID: 24580828 DOI: 10.1111/ajt.12667] [Cited by in Crossref: 133] [Cited by in F6Publishing: 117] [Article Influence: 16.6] [Reference Citation Analysis]
10 Couchonnal E, Rivet C, Ducreux S, Dumortier J, Bosch A, Boillot O, Collardeau-Frachon S, Dubois R, Hervieu V, André P, Scoazec JY, Lachaux A, Dubois V, Guillaud O. Deleterious impact of C3d-binding donor-specific anti-HLA antibodies after pediatric liver transplantation. Transpl Immunol 2017;45:8-14. [PMID: 28782692 DOI: 10.1016/j.trim.2017.08.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
11 Mccaughan JA, Robertson V, Falconer SJ, Cryer C, Turner DM, Oniscu GC. Preformed donor-specific HLA antibodies are associated with increased risk of early mortality after liver transplantation. Clin Transplant 2016;30:1538-44. [DOI: 10.1111/ctr.12851] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
12 Perera M, Silva M, Murphy N, Briggs D, Mirza D, Neil D. Influence of preformed donor-specific antibodies and C4d on early liver allograft function. Scandinavian Journal of Gastroenterology 2013;48:1444-51. [DOI: 10.3109/00365521.2013.845795] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
13 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Kamar N. Donor-specific antibodies and liver transplantation. Hum Immunol. 2016; Feb 23. [Epub ahead of print]. [PMID: 26916836 DOI: 10.1016/j.humimm.2016.02.006] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 5.7] [Reference Citation Analysis]
14 Burghuber C, Roberts T, Knechtle S. The clinical relevance of alloantibody in liver transplantation. Transplantation Reviews 2015;29:16-22. [DOI: 10.1016/j.trre.2014.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Tanaka A, Ide K, Tanaka Y, Ohira M, Tahara H, Ohdan H. B cell depletion with anti-CD20 mAb exacerbates anti-donor CD4+ T cell responses in highly sensitized transplant recipients. Sci Rep 2021;11:18180. [PMID: 34518640 DOI: 10.1038/s41598-021-97748-9] [Reference Citation Analysis]
16 Ünlü S, Lachmann N, Jara M, Ritschl PV, Wiering L, Eurich D, Denecke C, Biebl M, Chopra S, Gül-Klein S, Schöning W, Schmelzle M, Reinke P, Tacke F, Pratschke J, Öllinger R, Dziodzio T. Treatment of Anti-HLA Donor-Specific Antibodies Results in Increased Infectious Complications and Impairs Survival after Liver Transplantation. J Clin Med 2020;9:E3986. [PMID: 33317012 DOI: 10.3390/jcm9123986] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Del Bello A, Congy-Jolivet N, Muscari F, Lavayssière L, Esposito L, Cardeau-Desangles I, Guitard J, Dörr G, Suc B, Duffas JP, Alric L, Bureau C, Danjoux M, Guilbeau-Frugier C, Blancher A, Rostaing L, Kamar N. Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients. Am J Transplant 2014;14:867-75. [PMID: 24580771 DOI: 10.1111/ajt.12651] [Cited by in Crossref: 79] [Cited by in F6Publishing: 66] [Article Influence: 9.9] [Reference Citation Analysis]
18 Kovandova B, Slavcev A, Sekerkova Z, Honsova E, Trunecka P. Antibody-mediated rejection after liver transplantation-relevance of C1q and C3d-binding antibodies. HLA 2018;92:34-7. [DOI: 10.1111/tan.13354] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
19 Kohut TJ, Barandiaran JF, Keating BJ. Genomics and Liver Transplantation: Genomic Biomarkers for the Diagnosis of Acute Cellular Rejection. Liver Transpl 2020;26:1337-50. [DOI: 10.1002/lt.25812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Zimmerman MA, Schiller J, Kim J, Martin A, Selim M, Nydam TL, Cronin D 2nd, Hong JC. Pathologic sequelae of allosensitization in liver transplantation. J Surg Res 2016;200:195-9. [PMID: 26253457 DOI: 10.1016/j.jss.2015.06.047] [Reference Citation Analysis]
21 O'leary JG, Demetris AJ, Philippe A, Freeman R, Cai J, Heidecke H, Smith C, Hart B, Jennings LW, Catar R, Everly M, Klintmalm GB, Dragun D. Non-HLA Antibodies Impact on C4d Staining, Stellate Cell Activation and Fibrosis in Liver Allografts. Transplantation 2017;101:2399-409. [DOI: 10.1097/tp.0000000000001853] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 4.8] [Reference Citation Analysis]
22 Mallon DH, Bradley JA, Taylor CJ, Kosmoliaptsis V. Structural and electrostatic analysis of HLA B-cell epitopes: inference on immunogenicity and prediction of humoral alloresponses. Curr Opin Organ Transplant 2014;19:420-7. [PMID: 24977436 DOI: 10.1097/MOT.0000000000000108] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 3.1] [Reference Citation Analysis]
23 O'Leary JG, Kaneku H, Banuelos N, Jennings LW, Klintmalm GB, Terasaki PI. Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation. Am J Transplant 2015;15:1003-13. [PMID: 25772599 DOI: 10.1111/ajt.13153] [Cited by in Crossref: 99] [Cited by in F6Publishing: 87] [Article Influence: 14.1] [Reference Citation Analysis]
24 Adams DH, Sanchez-Fueyo A, Samuel D. From immunosuppression to tolerance. J Hepatol. 2015;62:S170-S185. [PMID: 25920086 DOI: 10.1016/j.jhep.2015.02.042] [Cited by in Crossref: 83] [Cited by in F6Publishing: 72] [Article Influence: 13.8] [Reference Citation Analysis]
25 Del Bello A, Neau‐cransac M, Lavayssiere L, Dubois V, Congy‐jolivet N, Visentin J, Danjoux M, Le Bail B, Hervieu V, Boillot O, Antonini T, Kamar N, Dumortier J. Outcome of Liver Transplant Patients With Preformed Donor‐Specific Anti–Human Leukocyte Antigen Antibodies. Liver Transpl 2019;26:256-67. [DOI: 10.1002/lt.25663] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
26 Kim H, Yi N, Song EY, Lee K, Lee K, Lee HW, Ahn HY, Yoon KC, Hong SK, Suh K. Preformed donor-specific antibodies do not affect the 1-year allograft survival in living donor liver transplantation. Clin Transplant 2018;32:e13244. [DOI: 10.1111/ctr.13244] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
27 Akamatsu N, Hasegawa K, Sakamoto S, Ohdan H, Nakagawa K, Egawa H. Rituximab Desensitization in Liver Transplant Recipients With Preformed Donor-specific HLA Antibodies: A Japanese Nationwide Survey. Transplant Direct 2021;7:e729. [PMID: 34291151 DOI: 10.1097/TXD.0000000000001180] [Reference Citation Analysis]
28 Vandevoorde K, Ducreux S, Bosch A, Guillaud O, Hervieu V, Chambon-Augoyard C, Poinsot D, André P, Scoazec JY, Robinson P, Boillot O, Dubois V, Dumortier J. Prevalence, Risk Factors, and Impact of Donor-Specific Alloantibodies After Adult Liver Transplantation. Liver Transpl 2018;24:1091-100. [PMID: 29665189 DOI: 10.1002/lt.25177] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
29 Cuadrado A, San Segundo D, López-Hoyos M, Crespo J, Fábrega E. Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation. World J Gastroenterol 2015; 21(39): 11016-11026 [PMID: 26494958 DOI: 10.3748/wjg.v21.i39.11016] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
30 Tran L, Humar A. Tolerance studies in liver transplantation: are we fooling ourselves? Current Opinion in Organ Transplantation 2020;25:151-7. [DOI: 10.1097/mot.0000000000000738] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
31 O'Leary JG, Cai J, Freeman R, Banuelos N, Hart B, Johnson M, Jennings LW, Kaneku H, Terasaki PI, Klintmalm GB. Proposed Diagnostic Criteria for Chronic Antibody-Mediated Rejection in Liver Allografts. Am J Transplant. 2016;16:603-614. [PMID: 26469278 DOI: 10.1111/ajt.13476] [Cited by in Crossref: 64] [Cited by in F6Publishing: 47] [Article Influence: 9.1] [Reference Citation Analysis]
32 Kovandova B, Slavcev A, Honsova E, Erhartova D, Skibova J, Viklicky O, Trunecka P. De novo HLA Class II antibodies are associated with the development of chronic but not acute antibody-mediated rejection after liver transplantation - a retrospective study. Transpl Int 2020;33:1799-806. [PMID: 33020979 DOI: 10.1111/tri.13763] [Reference Citation Analysis]
33 Grabhorn E, Binder TM, Obrecht D, Brinkert F, Lehnhardt A, Herden U, Peine S, Nashan B, Ganschow R, Briem-Richter A. Long-term Clinical Relevance of De Novo Donor-Specific Antibodies After Pediatric Liver Transplantation. Transplantation. 2015;99:1876-1881. [PMID: 25706279 DOI: 10.1097/tp.0000000000000638] [Cited by in Crossref: 44] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
34 Arias M, Serón D, Herrero I, Rush DN, Wiebe C, Nickerson PW, Ussetti P, Rodrigo E, de Cos M. Subclinical Antibody-Mediated Rejection. Transplantation 2017;101:S1-S18. [DOI: 10.1097/tp.0000000000001735] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Schiano TD, Florman S, Fiel MI. Recurrent Idiopathic Liver Allograft Failure. Am J Clin Pathol 2019;152:369-76. [PMID: 31139817 DOI: 10.1093/ajcp/aqz044] [Reference Citation Analysis]
36 Sultani B, Marget M, Briem-Richter A, Herrmann J, Meisner S, Grabhorn EF, Ozga AK, Weidemann S, Herden U, Fischer L, Sterneck M. Presence of donor specific HLA class 2 antibodies (DSA class 2) is associated with development of graft fibrosis more than 10 years after liver transplantation-a retrospective single center study. Clin Transplant 2021;35:e14336. [PMID: 33949011 DOI: 10.1111/ctr.14336] [Reference Citation Analysis]
37 Rahimi RS, O'leary JG. Transfusing common sense instead of blood products into coagulation testing in patients with cirrhosis: Overtreatment ≠ safety. Hepatology 2016;63:368-70. [DOI: 10.1002/hep.28291] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
38 Schluckebier D, Cousin VL, Petit L, Belli D, Wildhaber B, Rougemont A, Villard J, Ferrari‐lacraz S, Mclin VA. Preformed and de novo DSA are associated with T‐cell–mediated rejection in pediatric liver transplant recipients requiring clinically indicated liver biopsy. Pediatr Transplant 2020;24. [DOI: 10.1111/petr.13611] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
39 Del Bello A, Danjoux M, Congy-jolivet N, Lavayssière L, Esposito L, Muscari F, Kamar N. Histological long-term outcomes from acute antibody-mediated rejection following ABO-compatible liver transplantation: Outcome of antibody mediated rejection. Journal of Gastroenterology and Hepatology 2017;32:887-93. [DOI: 10.1111/jgh.13613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
40 Legaz I, Boix F, López M, Alfaro R, Galián JA, Llorente S, Campillo JA, Botella C, Ramírez P, Sánchez-Bueno F, Pons JA, Moya-Quiles MR, Minguela A, Muro M. Influence of Preformed Antibodies in Liver Transplantation. J Clin Med 2020;9:E708. [PMID: 32151032 DOI: 10.3390/jcm9030708] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
41 Matsuda Y, Sarwal MM. Unraveling the Role of Allo-Antibodies and Transplant Injury. Front Immunol 2016;7:432. [PMID: 27818660 DOI: 10.3389/fimmu.2016.00432] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
42 den Dulk AC, Shi X, Verhoeven CJ, Dubbeld J, Claas FHJ, Wolterbeek R, Brand-schaaf SH, Verspaget HW, Sarasqueta AF, van der Laan LJW, Metselaar HJ, van Hoek B, Kwekkeboom J, Roelen DL. Donor-specific anti-HLA antibodies are not associated with nonanastomotic biliary strictures but both are independent risk factors for graft loss after liver transplantation. Clin Transplant 2018;32:e13163. [DOI: 10.1111/ctr.13163] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
43 Levitsky J, Feng S. Tolerance in clinical liver transplantation. Hum Immunol. 2018;79:283-287. [PMID: 29054397 DOI: 10.1016/j.humimm.2017.10.007] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 9.4] [Reference Citation Analysis]
44 Nilles KM, Levitsky J. Donor-Specific Antibodies in Liver Transplantation. Clin Liver Dis (Hoboken) 2020;15:13-6. [PMID: 32104571 DOI: 10.1002/cld.871] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 O'Leary JG, Michelle Shiller S, Bellamy C, Nalesnik MA, Kaneku H, Jennings LW, Isse K, Terasaki PI, Klintmalm GB, Demetris AJ. Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features. Liver Transpl 2014;20:1244-55. [PMID: 25045154 DOI: 10.1002/lt.23948] [Cited by in Crossref: 60] [Cited by in F6Publishing: 46] [Article Influence: 8.6] [Reference Citation Analysis]
46 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Hebral AL, Bellière J, Kamar N. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World J Gastroenterol 2018; 24(16): 1795-1802 [PMID: 29713132 DOI: 10.3748/wjg.v24.i16.1795] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
47 Mehra NK, Baranwal AK. Clinical and immunological relevance of antibodies in solid organ transplantation. Int J Immunogenet 2016;43:351-68. [DOI: 10.1111/iji.12294] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
48 Taner T, Stegall MD, Heimbach JK. Antibody-mediated rejection in liver transplantation: current controversies and future directions. Liver Transpl 2014;20:514-27. [PMID: 24470340 DOI: 10.1002/lt.23826] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
49 Jain V, Dhawan A. Acute antibody-mediated rejection in the liver allograft: A masquerade or new disease? Pediatr Transplant 2017;21. [PMID: 28127881 DOI: 10.1111/petr.12869] [Reference Citation Analysis]
50 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Cardeau-Desangles I, Guitard J, Dörr G, Milongo D, Suc B, Duffas JP, Alric L, Bureau C, Guilbeau-Frugier C, Rostaing L, Kamar N. De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients. Transpl Int. 2015;28:1371-1382. [PMID: 26303035 DOI: 10.1111/tri.12654] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 9.0] [Reference Citation Analysis]
51 Jucaud V, Shaked A, DesMarais M, Sayre P, Feng S, Levitsky J, Everly MJ. Prevalence and Impact of De Novo Donor-Specific Antibodies During a Multicenter Immunosuppression Withdrawal Trial in Adult Liver Transplant Recipients. Hepatology. 2019;69:1273-1286. [PMID: 30229989 DOI: 10.1002/hep.30281] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
52 O'Leary JG, Smith C, Cai J, Hart B, Jennings LW, Everly M, Klintmalm GB, Demetris AJ. Chronic AMR in Liver Transplant: Validation of the 1-Year cAMR Score's Ability to Determine Long-term Outcome. Transplantation 2017;101:2062-70. [PMID: 28452922 DOI: 10.1097/TP.0000000000001802] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
53 Vallin P, Désy O, Béland S, Wagner E, De Serres SA. Clinical relevance of circulating antibodies and B lymphocyte markers in allograft rejection. Clin Biochem 2016;49:385-93. [PMID: 26721422 DOI: 10.1016/j.clinbiochem.2015.12.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
54 Ducreux S, Guillaud O, Bosch A, Thaunat O, Morelon E, Hervieu V, Mekki Y, Boillot O, Scoazec J, Dubois V, Dumortier J. Monitoring efficiency of humoral rejection episode therapy in liver transplantation: any role for complement binding Luminex Single Antigen assays? Transplant Immunology 2016;35:23-8. [DOI: 10.1016/j.trim.2016.01.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
55 Wadström J, Ericzon BG, Halloran PF, Bechstein WO, Opelz G, Serón D, Grinyó J, Loupy A, Kuypers D, Mariat C, Clancy M, Jardine AG, Guirado L, Fellström B, O'Grady J, Pirenne J, O'Leary JG, Aluvihare V, Trunečka P, Baccarani U, Neuberger J, Soto-Gutierrez A, Geissler EK, Metzger M, Gray M. Advancing Transplantation: New Questions, New Possibilities in Kidney and Liver Transplantation. Transplantation 2017;101 Suppl 2S:S1-S41. [PMID: 28125449 DOI: 10.1097/TP.0000000000001563] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.8] [Reference Citation Analysis]
56 Xu Q, Mcalister VC, Leckie S, House AA, Skaro A, Marotta P. Angiotensin II type I receptor agonistic autoantibodies are associated with poor allograft survival in liver retransplantation. Am J Transplant 2019;20:282-8. [DOI: 10.1111/ajt.15571] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
57 Taylor M, Jefferies J, Byrne B, Lima J, Ambale-Venkatesh B, Ostovaneh MR, Makkar R, Goldstein B, Smith RR, Fudge J, Malliaras K, Fedor B, Rudy J, Pogoda JM, Marbán L, Ascheim DD, Marbán E, Victor RG. Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial. Neurology 2019;92:e866-78. [PMID: 30674601 DOI: 10.1212/WNL.0000000000006950] [Cited by in Crossref: 32] [Cited by in F6Publishing: 11] [Article Influence: 10.7] [Reference Citation Analysis]
58 Demetris AJ, Bellamy C, Hübscher SG, O’Leary J, Randhawa PS, Feng S, Neil D, Colvin RB, McCaughan G, Fung JJ. 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. Am J Transplant. 2016; Epub ahead of print. [PMID: 27273869 DOI: 10.1111/ajt.13909] [Cited by in Crossref: 230] [Cited by in F6Publishing: 187] [Article Influence: 38.3] [Reference Citation Analysis]
59 Wesson RN, Etchill EW, Garonzik-Wang J. Application and interpretation of histocompatibility data in liver transplantation. Curr Opin Organ Transplant. 2017;22:499-504. [PMID: 28708813 DOI: 10.1097/mot.0000000000000450] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
60 Del Bello A, Thaunat O, Le Quintrec M, Bestard O, Durrbach A, Perrin P, Gatault P, Jambon F, Pageaux GP, Llado L, Besch C, Barbier L, Neau-Cransac M, Dumortier J, Kamar N. Combined Liver-Kidney Transplantation With Preformed Anti-human Leukocyte Antigen Donor-Specific Antibodies. Kidney Int Rep 2020;5:2202-11. [PMID: 33305113 DOI: 10.1016/j.ekir.2020.09.018] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 O'Leary JG, Kaneku H, Demetris AJ, Marr JD, Shiller SM, Susskind BM, Tillery GW, Terasaki PI, Klintmalm GB. Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl 2014;20:218-27. [PMID: 24382837 DOI: 10.1002/lt.23788] [Cited by in Crossref: 74] [Cited by in F6Publishing: 62] [Article Influence: 9.3] [Reference Citation Analysis]
62 Ravindranath MH, Terasaki PI, Maehara CY, Jucaud V, Kawakita S, Pham T, Yamashita W. Immunoglobulin (Ig)G purified from human sera mirrors intravenous Ig human leucocyte antigen (HLA) reactivity and recognizes one's own HLA types, but may be masked by Fab complementarity-determining region peptide in the native sera. Clin Exp Immunol 2015;179:309-28. [PMID: 25196542 DOI: 10.1111/cei.12450] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
63 Demetris AJ, Zeevi A, O'Leary JG. ABO-compatible liver allograft antibody-mediated rejection: an update. Curr Opin Organ Transplant. 2015;20:314-324. [PMID: 25944231 DOI: 10.1097/mot.0000000000000194] [Cited by in Crossref: 38] [Cited by in F6Publishing: 6] [Article Influence: 5.4] [Reference Citation Analysis]
64 Thomson AW, Vionnet J, Sanchez-Fueyo A. Understanding, predicting and achieving liver transplant tolerance: from bench to bedside. Nat Rev Gastroenterol Hepatol 2020;17:719-39. [PMID: 32759983 DOI: 10.1038/s41575-020-0334-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
65 Haas M. Simultaneous liver-kidney transplantation: shifting renal allograft gene expression from inflammation toward preservation. Kidney Int 2017;91:1010-3. [PMID: 28407877 DOI: 10.1016/j.kint.2017.02.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
66 Höfer A, Jonigk D, Hartleben B, Verboom M, Hallensleben M, Manns MP, Jaeckel E, Taubert R. Non-invasive screening for subclinical liver graft injury in adults via donor-specific anti-HLA antibodies. Sci Rep 2020;10:14242. [PMID: 32859929 DOI: 10.1038/s41598-020-70938-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
67 Liu W, Wang K, Xiao YL, Liu C, Gao W, Li DH. Clinical relevance of donor-specific human leukocyte antigen antibodies after pediatric liver transplantation. Exp Ther Med 2021;22:867. [PMID: 34194545 DOI: 10.3892/etm.2021.10299] [Reference Citation Analysis]
68 O'Leary JG, Kaneku H, Jennings L, Susskind BM, Terasaki PI, Klintmalm GB. Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients. Liver Transpl 2014;20:655-63. [PMID: 24678017 DOI: 10.1002/lt.23854] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
69 Wozniak LJ, Venick RS. Donor-specific antibodies following liver and intestinal transplantation: Clinical significance, pathogenesis and recommendations. International Reviews of Immunology 2019;38:106-17. [DOI: 10.1080/08830185.2019.1630404] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
70 O'Leary JG, Philippe A, Freeman R, Heidecke H, Jennings LW, Catar R, Klintmalm GB, Dragun D. Non-HLA Autoantibodies at 1 Year Negatively Affect 5-Year Native Renal Function in Liver Transplant Recipients. Transplant Proc 2021;53:1019-24. [PMID: 33579550 DOI: 10.1016/j.transproceed.2021.01.013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Xu Q, McAlister VC, House AA, Molinari M, Leckie S, Zeevi A. Autoantibodies to LG3 are associated with poor long-term survival after liver retransplantation. Clin Transplant 2021;35:e14318. [PMID: 33871888 DOI: 10.1111/ctr.14318] [Reference Citation Analysis]
72 Mckenna GJ, Klintmalm GB. Induction and Maintenance of Immunosuppression. Transplantation of the Liver. Elsevier; 2015. pp. 1264-88. [DOI: 10.1016/b978-1-4557-0268-8.00091-9] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
73 Oniscu GC, Diaz G, Levitsky J. Meeting report of the 19th Annual International Congress of the International Liver Transplantation Society (Sydney Convention and Exhibition Centre, Sydney, Australia, June 12-15, 2013). Liver Transpl 2014;20:7-14. [PMID: 24136728 DOI: 10.1002/lt.23767] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
74 Song SH, Kim MS, Lee JJ, Ju MK, Lee JG, Lee J, Choi JS, Choi GH, Kim SI, Joo DJ. Effect of donor-specific antibodies and panel reactive antibodies in living donor liver transplant recipients. Ann Surg Treat Res 2015;88:100-5. [PMID: 25692121 DOI: 10.4174/astr.2015.88.2.100] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
75 Dumortier J, Dedic T, Erard-poinsot D, Rivet C, Guillaud O, Chambon-augoyard C, Bosch A, Lachaux A, Couchonnal E, Thaunat O, Boillot O, Dubois V. Pregnancy and donor-specific HLA-antibody-mediated rejection after liver transplantation: “Liaisons dangereuses”? Transplant Immunology 2019;54:47-51. [DOI: 10.1016/j.trim.2019.02.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
76 Koch M, Marget M, Sterneck M, Fischer L, Thude H, Nashan B. Limited impact of pre-existing donor specific HLA-antibodies (DSA) on long term allograft survival after first adult liver transplantation. Hum Immunol 2018;79:545-9. [PMID: 29669260 DOI: 10.1016/j.humimm.2018.04.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
77 Willuweit K, Frey A, Bieniek L, Heinold A, Büchter M, Horn PA, Wedemeyer H, Herzer K. HLA class II donor specific antibodies are associated with graft cirrhosis after liver transplant independent of the mean fluorescence intensity level. BMC Gastroenterol 2020;20:288. [PMID: 32854625 DOI: 10.1186/s12876-020-01427-4] [Reference Citation Analysis]
78 Bolarín JM, Pérez-Cárceles MD, Hernández Del Rincón JP, Luna A, Minguela A, Muro M, Legaz I. Causes of Death and Survival in Alcoholic Cirrhosis Patients Undergoing Liver Transplantation: Influence of the Patient's Clinical Variables and Transplant Outcome Complications. Diagnostics (Basel) 2021;11:968. [PMID: 34072173 DOI: 10.3390/diagnostics11060968] [Reference Citation Analysis]
79 Thorsen T, Dahlgren US, Aandahl EM, Grzyb K, Karlsen TH, Boberg KM, Rydberg L, Naper C, Foss A, Bennet W. Liver transplantation with deceased ABO-incompatible donors is life-saving but associated with increased risk of rejection and post-transplant complications. Transpl Int 2015;28:800-12. [PMID: 25736519 DOI: 10.1111/tri.12552] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
80 Hogen R, DiNorcia J, Dhanireddy K. Antibody-mediated rejection: what is the clinical relevance? Curr Opin Organ Transplant 2017;22:97-104. [PMID: 28060025 DOI: 10.1097/MOT.0000000000000391] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
81 Neuberger JM, Bechstein WO, Kuypers DR, Burra P, Citterio F, De Geest S, Duvoux C, Jardine AG, Kamar N, Krämer BK, Metselaar HJ, Nevens F, Pirenne J, Rodríguez-Perálvarez ML, Samuel D, Schneeberger S, Serón D, Trunečka P, Tisone G, van Gelder T. Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group. Transplantation 2017;101:S1-S56. [PMID: 28328734 DOI: 10.1097/TP.0000000000001651] [Cited by in Crossref: 114] [Cited by in F6Publishing: 43] [Article Influence: 22.8] [Reference Citation Analysis]
82 Tamura K, Tohyama T, Watanabe J, Nakamura T, Ueno Y, Inoue H, Honjo M, Sakamoto K, Takai A, Ogawa K, Takada Y. Preformed donor-specific antibodies are associated with 90-day mortality in living-donor liver transplantation. Hepatol Res 2019;49:929-41. [PMID: 30991451 DOI: 10.1111/hepr.13352] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
83 Kim SC, Foley DP. Donor-specific antibodies in liver transplantation: challenges in diagnosis and determining clinical impact. Curr Opin Organ Transplant 2020;25:549-54. [PMID: 33105198 DOI: 10.1097/MOT.0000000000000825] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]